Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PADDOCK: Pegcetacoplan in PNH
NCT02588833Phase 1Completed
- Sponsor
- Apellis Pharmaceuticals
- Start
- Dec 2015
- Primary completion
- Aug 2019
- Modality
- PEGylated Peptides
- Countries
- 4
01
Overview
Phase 1, open-label trial of pegcetacoplan in paroxysmal nocturnal hemoglobinuria (PNH) (2 cohorts), sponsored by Apellis Pharmaceuticals. Primary endpoints: Treatment Emergent Adverse Events, Change in Lactate Dehydrogenase at Day 365 and 3 more. Started Dec 2015; status: completed.
02
Drugs
pegcetacoplan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT02588833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02588833.